Evidence map›Paper›PMID 34064300›Full record

ReviewPathogens (Basel, Switzerland)2021

Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2.

Nikola Hudakova, Simona Hricikova, Amod Kulkarni, Mangesh Bhide, Eva Kontsekova, Dasa Cizkova

Abstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nikola HudakovaCentre for Experimental and Clinical Regenerative Medicine, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia.ORCID 0000-0002-0941-2357
Simona HricikovaLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia.ORCID 0000-0001-9650-4737
Amod KulkarniLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia.
Mangesh BhideLaboratory of Biomedical Microbiology and Immunology, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia.
Eva KontsekovaInstitute of Neuroimmunology, Slovak Academy of Sciences, 84505 Bratislava, Slovakia.
Dasa CizkovaCentre for Experimental and Clinical Regenerative Medicine, The University of Veterinary Medicine and Pharmacy, 04181 Kosice, Slovakia.ORCID 0000-0002-2504-3993

Funding

Agentúra na Podporu Výskumu a Vývoja APVV-18-0259Agentúra na Podporu Výskumu a Vývoja APVV-19-0193Agentúra na Podporu Výskumu a Vývoja PP-COVID-20-0044
6 · The paper itself

Abstract

Coronavirus disease (COVID-19) caused by the SARS-CoV-2 virus has been affecting the world since the end of 2019. The severity of the disease can range from an asymptomatic or mild course to acute respiratory distress syndrome (ARDS) with respiratory failure, which may lead to death. Since the outbreak of the pandemic, scientists around the world have been studying the genome and molecular mechanisms of SARS-CoV-2 infection to develop effective therapies and prevention. In this review, we summarize the progressive development of various treatments and vaccines as they have emerged, a year after the outbreak of the pandemic. Initially for COVID-19, patients were recommended drugs with presumed antiviral, anti-inflammatory, and antimicrobial effects that were previously used to treat other diseases. Thereafter, therapeutic interventions were supplemented with promising approaches based on antibodies, peptides, and stem cells. However, licensed COVID-19 vaccines remain the most effective weapon in combating the pandemic. While there is an enormous effort to enhance the vaccination rate to increase the entire population immunity, the production and delivery of vaccines is becoming limited in several countries. In this regard, there are new challenges needing to be addressed by combining non-pharmacological intervention with effective therapies until vaccination is accessible to all.

Indexed as

antibodiesCOVID-19cytokine stormSARS-CoV-2therapyvaccines

Identifiers

PMID34064300
PMCPMC8224379

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.